Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

TLR4 agonists as immunomodulatory agents.

Mark R Alderson1, Patrick McGowan, Jory R Baldridge

  • 1GlaxoSmithKline Biologicals North America, Seattle, WA, USA.

Journal of Endotoxin Research
|October 25, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

3D Printing with Marine Gelatin: A Cross-Sector Review of Biomedical, Food, and Health Uses.

Marine drugs·2026
Same author

Independent effects of depression and elevated body mass index on maternal CRP levels in pregnancy.

Journal of affective disorders·2025
Same author

Development of MenFive®, an affordable pentavalent meningococcal conjugate vaccine (ACYWX) for Africa and beyond.

Human vaccines & immunotherapeutics·2025
Same author

Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine targeting serogroups A, C, W, Y, and X when co-administered with routine childhood vaccines at ages 9 months and 15 months in Mali: a single-centre, double-blind, randomised, controlled, phase 3, non-inferiority trial.

Lancet (London, England)·2025
Same author

Meningococcal Vaccine in Mali and Gambia. Reply.

The New England journal of medicine·2023
Same author

Meningococcal ACWYX Conjugate Vaccine in 2-to-29-Year-Olds in Mali and Gambia.

The New England journal of medicine·2023

Synthetic immune stimulants called aminoalkyl glucosaminide phosphates (AGPs) show potential as mucosal vaccine adjuvants. These compounds enhance innate and adaptive immunity, offering immediate protection and long-term acquired immunity against pathogens.

Area of Science:

  • Immunology
  • Vaccinology
  • Synthetic Chemistry

Background:

  • Monophosphoryl lipid A (MPL) is a licensed vaccine adjuvant derived from Salmonella minnesota.
  • MPL signals through the Toll-like receptor 4 (TLR4)/MD-2 complex.
  • There is a need for novel vaccine adjuvants, particularly for mucosal administration.

Purpose of the Study:

  • To synthesize and characterize novel TLR4 agonists based on MPL structure.
  • To evaluate the immunomodulatory and adjuvant properties of these synthetic agonists, termed aminoalkyl glucosaminide phosphates (AGPs).
  • To explore the potential of AGPs in developing advanced mucosal vaccines.

Main Methods:

  • Synthesis of a series of aminoalkyl glucosaminide phosphates (AGPs).
  • In vitro studies using human peripheral blood mononuclear cells (PBMCs) to assess cytokine production and cell surface marker expression.

Related Experiment Videos

  • In vivo studies in mice to evaluate non-specific resistance to viral and bacterial challenge after airway administration.
  • Structure-activity relationship (SAR) studies to identify key molecular determinants for immune activation.

    • Main Results:

    • AGPs effectively stimulate cytokine production and up-regulate cell surface markers on immune cells (monocytes, NK cells, B cells).
    • Airway administration of AGPs confers non-specific resistance against viral and bacterial pathogens in mice.
    • SAR studies indicate that acyl chain length and aglycon functional groups are critical for AGP activity.
    • AGPs act as potent adjuvants for mucosal vaccine antigens, enhancing both antibody and cell-mediated immune responses.

    Conclusions:

    • AGPs are potent synthetic TLR4 agonists with significant immunomodulatory and adjuvant properties.
    • AGPs can induce innate resistance and enhance adaptive immunity when administered mucosally.
    • The findings suggest that AGPs hold promise for the development of next-generation mucosal vaccines offering immediate innate protection and durable acquired immunity.